Company is exploring potential strategic opportunities and non-dilutive sources of capital, and partnerships Continued activities of the first Phase 3 clinical trial for celiac.

Innovate Biopharmaceuticals, Inc. (INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, announced the start of the first phase 3 clinical trial in celiac disease. Innovate’s Chief Medical Officer, Dr. Patrick H. Griffin, stated, “We are proud to start the first ever phase 3 clinical trial to address a large unmet need for celiac patient suffering from continued symptoms in spite of being on a gluten-free diet.” Innovate’s Chairman and CEO, Dr. Sandeep Laumas, added, “This is a landmark event in the history of celiac disease for the first ever phase 3 trial to get underway as well as a key pivotal moment for Innovate. Innovate is a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases.

RALEIGH, NC / ACCESSWIRE / March 11, 2020 / Innovate Biopharmaceuticals, Inc. (INNT), a clinical-stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, expects to close the merger with RDD Pharma Ltd. around the end of the first quarter of 2020. All parties to the proposed merger are actively involved in monitoring progress with the regulatory agencies. Innovate is a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases.

Innovate Biopharmaceuticals, Inc. (INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, today announced the appointment of Ed Sitar as its Chief Financial Officer commencing on July 1, 2019. With an expanded management team, Innovate intends to focus on non-dilutive sources of capital to further develop its pipeline, including out-licensing of (i) selective ex-US rights to INN-202 for celiac disease and (ii) Innovate’s earlier clinical stage pipeline of drug product candidates.  In addition, Innovate intends to suspend future sales of shares under its “at-the-market” established pursuant to its common stock sales agreement with H.C. Wainwright & Co., LLC and Ladenburg Thalmann & Co. Inc.

Innovate Biopharmaceuticals, Inc. (INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, today announced the commencement of succession planning activities for its chief executive officer. The company expects to search for a permanent chief executive officer to work with the management team on progressing the current Phase 3 celiac disease trial of larazotide acetate and identifying and pursuing potential non-dilutive sources of capital.

Completes concurrent financing of ~$22 million led by Orbimed Advisors, LLC Lead program, a proprietary long-acting GLP-1 receptor agonist, starting Phase 2 trial for Short Bowel Syndrome (SBS), an underserved, ...

Highlighting Larazotide's Effect across the Gut-Vascular Barrier - a Fundamental Disease Mechanism in a Variety of Autoimmune and Inflammatory Diseases RALEIGH, NC / ACCESSWIRE / February 19, 2020 / Innovate ...

Even the best investor on earth makes unsuccessful investments. But serious investors should think long and hard about...

Global concerns over the spread of the novel coronavirus rocked stock markets on Monday. The spread of COVID-19 has been a major economic punch felt around the globe, and it's impacting production at Triangle firms – from Lenovo to Cree.

TEL AVIV, Israel and RICHMOND, Calif., Nov. 13, 2019 /PRNewswire/ -- RDD Pharma, Ltd. ("RDD"), a company focused on orphan and innovative therapies for gastrointestinal disorders entered into a non-binding letter of intent ("LOI") to acquire Naia Rare Diseases ("Naia"), a biopharmaceutical company developing drugs for Short Bowel Syndrome ("SBS") and other rare gastrointestinal diseases. Closing of the transaction is anticipated to occur after the consummation of the proposed merger of RDD and Innovate Biopharmaceuticals, Inc. (INNT) which will form a combined company (the "INNT Merger") intended to be named 9 Meters Biopharma, Inc. In exchange, Naia will receive a combination of cash and shares in 9 Meters Biopharma subject to closing of the INNT Merger.

RALEIGH, NC and TEL AVIV, ISRAEL / ACCESSWIRE / October 7, 2019 / Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases ("Innovate"), and RDD Pharma, Ltd. focused on orphan and innovative therapies for gastrointestinal disorders ("RDD"), announced today that the two companies entered into a definitive merger agreement pursuant to which Innovate agreed to acquire all of the outstanding capital stock of privately-held RDD in exchange for a combination of common and preferred shares. After the merger closing, Innovate will be renamed 9 Meters Biopharma, Inc. Innovate believes that the proposed transaction will position the combined company to recognize multiple value inflection points over the next 24 months based on the combined clinical pipeline, seasoned Board of Directors and world class management and prominent healthcare-dedicated institutional investors.

The planned merger of a Triangle company and an Israeli outfit has brought in a third company -- and leadership says it could be the makings of a "new Salix" for Raleigh.

The merger of a Triangle public drugmaker and an Israeli outfit led by former-Salix executives could have huge potential for Raleigh and its gastrointestinal candidates.

Innovate Biopharmaceuticals, Inc. (“Innovate”) (INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, today announced that it has dosed the first patient in its Phase 3 clinical trial, CeD LA 3001. This marks the first time any company has dosed a patient in a Phase 3 trial for celiac disease. Larazotide acetate, or INN-202, is Innovate's leading drug candidate for the treatment of celiac disease.

RALEIGH, NC / ACCESSWIRE / March 20, 2020 / Innovate Biopharmaceuticals, Inc. (the "Company" or "Innovate") (INNT), a clinical stage biotechnology company focused on developing novel autoimmune and inflammation therapeutics, announced that it has filed its 2019 Annual Report on Form 10-K today. · The closing of merger with RDD Pharma Ltd. is expected around the end of the first quarter/beginning of the second quarter of 2020. The merged company renamed 9 Meters Biopharma, Inc., will create a platform company focusing on rare, orphan, and unmet needs in gastrointestinal disorders.

RALEIGH, NC / ACCESSWIRE / February 18, 2020 / Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT - "Innovate"), a clinical stage biotechnology company focused on developing novel therapeutics announced the results from its February 14, 2020 special meeting of shareholders to approve proposals related to its upcoming merger with RDD Pharma Ltd. ("RDD").